Transforming Bold Science into Therapeutic Breakthroughs

Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.

Carmot is a clinical-stage company dedicated to the discovery and development of innovative medicines. Using Chemotype Evolution, a transformative, patented drug discovery approach, Carmot was acquired by Roche in December 2023 for $3.3B.

Peloton Therapeutics is advancing a first-in-class discovery and development pipeline in oncology, comprising several well-differentiated small-molecule programs. Peloton was acquired by Merck in May 2019 for up to $2.35B.

Aragon is creating a new class of nuclear receptor targeting drugs that overcome the biology of hormone resistant cancers. Aragon was acquired by Johnson & Johnson in August 2013 for up to $1B.

Seragon is focused on developing new treatments for estrogen-driven cancers based on its Selective Estrogen Receptor Degrader (SERD) platform. Seragon was acquired by Genentech, a member of the Roche Group, in August 2014 for $0.8B.

Neurona is a cell therapy company focused on the discovery and development of disease-altering treatments for intractable neuropsychiatric disorders. The company seeks to become an industry leader in the neural stem cell field with multiple therapeutic product candidates.

Constellation is a pioneer in the discovery and development of novel therapeutics that target the writer, reader and eraser classes of epigenetic regulators and modulate gene expression in a more selective manner. Constellation was acquired by MorphoSys on June 2, 2021 for $1.7B.

Exonics discovers and develops medicines for the treatment of neuromuscular diseases. The Company develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of Duchenne muscular dystrophy mutations. Exonics was acquired by Vertex on June 6, 2019 for up to $1B.

Flexus was founded with the mission to create new cancer therapeutics through the innovative application of unexploited insights in immunology. Flexus Biosciences was acquired by Bristol-Myers Squibb in April 2015 for $1.3B.

ORIC is a small molecule oncology company focused on combating the growing resistance problem to current molecularly targeted drugs.

Tenaya is focused on creating therapeutics for heart failure patients. Tenaya seeks to address heart disease through three distinct and multi-modality platforms: a Regeneration Platform, a Gene Therapy Platform, and a Precision Medicine Platform.

Remix Therapeutics is developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Remix's innovative therapeutic solutions has the potential to address disease drivers at their origin.

NGM Bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform that has generated a pipeline of first-in-class biologic development candidates.

Velia is harnessing the therapeutic potential of a novel class of small human proteins, microproteins, which regulate biological functions vital to human health. Velia will discover and develop therapeutics targeting these potent regulators.

A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. A2 utilizes an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.

Accent Therapeutics is developing small molecule, precision cancer therapies in the emerging field of epitranscriptomics. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision drugs, Accent is translating extraordinary, novel science into life-changing therapies for patients.

Nura Bio (formerly Proneurotech) seeks to alter the course of neurological diseases by targeting fundamental pathways underlying axon degeneration and neuroimmune regulation to preserve neuronal integrity.

Plexium is focused on the identification of E3 ligase modulating small molecules to treat cancer and neurodegenerative diseases. Plexium’s platform allows screening for molecular-glue degraders to be conducted via massively high throughput cell-based assays utilizing DNA-encoded libraries.

Synthekine is focused on discovery and developing best in class cytokine therapeutics. The company is generating an array of “synthetic” cytokines and will deploy these unique molecules to tune the immune system in new and interesting ways for the potential treatment of a range of diseases, from cancer to autoimmune disorders.

InduPro seeks to discover and redefine cell-surface interactions to modulate biological pathways driving human diseases. InduPro platforms integrate inherent protein proximity at the cell surface with the ability to manipulate protein pairings using innovative molecular engineering to create novel signaling pathways.

RAPT Therapeutics (formerly FLX Bio) aims to conquer cancer and inflammatory disease in our lifetime. RAPT is fully focused on developing oral therapeutics that intelligently target key drivers of the immune system to transform the treatment of cancer and inflammation, and improve and empower countless lives.

Kallyope is dedicated to unlocking the therapeutic potential of the gut-brain axis. Kallyope integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health.

Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease. Cajal is inspired by the pioneering work of Nobel laureate Santiago Ramón y Cajal who illuminated the complexity of the brain by marrying art and science.

Hexagon's interdisciplinary platform discovers evolutionarily refined small molecules and their protein targets directly from fungal genomes. Hexagon then develops these molecules into therapeutics to combat human disease.

Tr1X is developing therapies intended to reset the immune system and promote tolerance. Our proprietary platform generates potent, targeted regulatory T cell-based products to cure immune and inflammatory diseases.

Lyterian is utilizing novel protein homeostasis mechanisms to degrade and therefore inhibit, genetically defined disease targets. Their initial focus will be on aggregated protein diseases, many of which are central to neurodegenerative disease.

Arcus Biosciences is an oncology company researching adaptive immunity and innate immunity to discover drugs with broad applicability in combination therapies.

Kimia's ATLAS platform combines high-throughput experimentation with machine learning to empower generative drug design. By combining ATLAS with gene editing, Kimia can identify novel targets amenable to therapeutic intervention and is creating a chemical atlas for treating oncology and immunological diseases.

Casma Therapeutics is harnessing the autophagy-lysosome pathway to enhance the clearance of disease causing proteins, signaling complexes, aggregates, organelles and pathogens as well as mechanisms to activate lysosomal-mediated membrane repair in diseases such as muscular dystrophy.

Escient Pharmaceuticals is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. Escient was acquired by Incyte in April 2024 for $783M.

Circle Pharma operates an indication-agnostic discovery engine for the development of cell permeable macrocyclic peptide therapeutics. Circle's discovery engine combines computational structure-based design with automated, fully synthetic chemistry.

Eikon Therapeutics is a new biopharmaceutical company employing the revolutionary technology of single molecule imaging at the intersection of chemistry, engineering and biology to discover novel treatments for life-threatening diseases.

Gritstone’s goal is to develop groundbreaking immunotherapies for cancers and infectious diseases. The Company's approach focuses on generating a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize and destroy tumors or virally-infected cells.

Immune Design is an immunotherapy oncology company focused on engineering technologies to activate the immune system’s natural ability to fight disease. Immune Design was acquired by Merck in February 2019 for $0.3B.

Nurix is focused on discovering and developing therapies that modulate the ubiquitin proteasome system (UPS) for the treatment of a broad range of human disorders, most notably cancer.

Kenai is pioneering the development and manufacture of novel off-the-shelf induced pluripotent stem cell (iPSC) based therapies for the treatment of neurodegenerative disorders, including Parkinson’s disease.

Revolution Medicines is an innovative and dynamic organization of expert cellular, structural and computational biologists, medicinal and synthetic chemists, pharmacologists, engineers and business executives working together to discover and develop new medicines for cancer patients.

Atavistik Bio is a pre-clinical stage biotechnology company pioneering the identification of allosteric small molecule-protein interactions that have the potential to lead to the discovery and future clinical development of first-in-class drug compounds within oncology and metabolic diseases.